RxDoctor Payments Data

Emmanuel Edoka, MD

Internal Medicine · Austin, TXNPI 1598857682

Payments from drug & device makers

$2,081in general payments, 2019–2025

Across 121 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$384
  • Amgen$365
  • Lilly USA, LLC$327
  • Astellas Pharma US Inc$224
  • Boehringer Ingelheim$211
  • Novo Nordisk$205
  • plus $364 from 10 others

What the payments were for

  • Food & beverage$1,95694%
  • Education$1256%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,081 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$18,080
Medicare patients
96
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide58$109,554
JardianceEmpagliflozin86$84,634
OzempicSemaglutide35$49,825
EliquisApixaban43$42,884
MyrbetriqMirabegron28$31,082
Tresiba Flextouch U-200Insulin Degludec17$29,836
MounjaroTirzepatide27$28,513
JanuviaSitagliptin Phosphate20$19,723
TradjentaLinagliptin12$15,033
LinzessLinaclotide12$12,768
Xigduo XrDapaglifloz Propaned/Metformin14$9,859
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen71$3,264
Atorvastatin Calcium340$2,939
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,764
Novolog FlexpenInsulin Aspart14$2,543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$327$138,06785 claims
Boehringer IngelheimJardiance, Tradjenta$211$99,66798 claims
Novo NordiskOzempic$205$49,82535 claims
Astellas Pharma US IncMyrbetriq$224$31,08228 claims
AbbVieLinzess, Synthroid$58$13,42123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →